Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
1.515
-0.125 (-7.62%)
Aug 20, 2026, 4:00 PM EDT - Market closed

Neumora Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-206.23-236.16-263.46-188.19-122.87-80.32
Net Income
-212.75-236.93-243.79-235.93-130.9-237.31
Earnings Per Share
-1.22-1.45-1.53-3.63-4.81-10.84
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
116.83182.53307.58463.83395.4409.25
Total Debt
53.2555.011.855.238.442.05
Net Cash (Debt)
63.58127.52305.73458.6386.95407.2
Net Cash Growth
-67.83%-58.29%-33.34%18.52%-4.97%114.39%
Net Cash Per Share
0.370.781.927.0514.2218.60

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-180.52-206.44-182.94-163.28-114.9-75.42
Capital Expenditures
---0.78-4.71-13.51-0.82
Free Cash Flow
-180.52-206.44-183.71-167.99-128.41-76.24
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.